The investigation centers on the fairness of the deal terms currently presented to investors of the NASDAQ-listed biotech company. Attorney Juan Monteverde, whose firm is recognized in the 2025 ISS Securities Class Action Services Report, is spearheading the review from their Empire State Building headquarters. Shareholders are being encouraged to evaluate the offer closely, as the firm aims to identify potential discrepancies in the valuation process.
In section Releases
Monteverde & Associates Launches Investigation into Pacira BioSciences Sale
A $36.50 cash-per-share offer for Pacira BioSciences Inc. has triggered a formal investigation by Monteverde & Associates PC. The New York-based firm is scrutinizing the proposed acquisition by Viatris Inc. to determine whether the transaction provides adequate value for shareholders or requires legal intervention to protect their financial interests.
Investors holding common stock in Pacira BioSciences can contact the firm to discuss their rights or to obtain further details regarding the ongoing review. Monteverde & Associates, which maintains a track record in trial and appellate courts, is offering consultations at no cost to those concerned about the impact of the Viatris transaction on their holdings.
Comments (0)
No comments yet. Be the first!